Pharmacokinetics of the recombinant thrombolytic agents: What is the clinical significance of their different pharmacokinetic parameters?

BioDrugs

Volumn 11, Issue 2, 1999, Pages 115-123

  Cohen, Adam ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; RECOMBINANT PROTEIN; RETEPLASE; SARUPLASE; STREPTOKINASE; UROKINASE;

BRAIN HEMORRHAGE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; REVIEW; THROMBOSIS; TREATMENT OUTCOME; URINARY EXCRETION;

EID: 0032989947     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199911020-00005     Document Type: Review

References (43)

1. European Cooperative study group for streptokinase treatment in acute myocardial infarction. Streptokinase in acute myocardial infarction. N Engl J Med 1979; 301: 797-802
2. Kennedy JW, Ritchie JL, Davis KB, et al. The Western Washington randomised trial of intracoronary streptokinase in acute myocardial infarction. N Engl J Med 1985; 312: 1073-8
3. ISIS-3. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753-70
4. GUSTO Investigators. An international randomised trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82
5. Vaughan DE, Braunwald E. Front-loaded accelerated infusions of tissue plasminogen activator: putting a better foot forward [editorial; comment]. J Am Coll Cardiol 1992; 19 (5): 1076-8
6. Tanswell P. Tebbe U, Neuhaus KL, et al. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute. J Am Coll Cardiol 1992; 19 (5): 1071-5
7. The Continuous infusion versus double-bolus administration of alteplase (COBALT) investigators. A comparison of continuous infusion of alteplasc with double-bolus administration for acute myocardial infarction. N Engl J Med 1997; 337 (16): 1124-30
8. Kluft C, Kluft C, editors. Tissue-type plasminogen activator (t-PA): Physiological and clinical aspects. 1st ed. Cleveland (OH): CRC Press Inc, 1988
9. Noe DA, Bell WR. A kinetic analysis of fibrinogenolysis during plasminogen activator therapy. Clin Pharmacol Ther 1987; 41: 297-303
10. Tiefenbrunn AJ, Graor RA, Robison AK, et al. Pharmacodynamics of tissue-type plasminogen activator characterised by computer-assisted simulation. Circulation 1986; 73: 1291-9
11. Seifried E, Muller MM, Martin U, et al. Bolus application of a novel recombinant plasminogen activator in acute myocardial infarction. Ann N Y Acad Sci 1992; 667: 417-20
12. Martin U, Mollendorfr EV, Akpan W, et al. Dose-ranging study of the novel recombinant plasminogen activator BM 06.022 in healthy volunteers. Clin Pharmacol Ther 1991; 50: 429-36
13. Martin A, Mollendorff EV, Akpan W, et al. Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator BM 06.022 in healthy volunteers. Thromb Haemostasis 1991; 66 (5): 569-74
14. Seifried E, Tanswell P, Ellbruck D, et al. Pharmacokinetics and haemostatic status during consecutive infusions of recombinant tissue-type plasminogen activator in patients with acute myocardial infarction. Thromb Haemost 1989; 61 (3): 497-501
15. Tanswell P, Seifried E, Su PC, et al. Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects. Clin Pharmacol Ther 1989; 46: 155-62
16. Tebbe U, Tanswell P, Seifried E, et al. Single-bolus injection of recombinant tissue-type plasminogen activator in acute myocardial infarction. Am J Cardiol 1989; 64: 448-53
17. Seifried E, Tanswell P, Rijken DC, et al. Pharmacokinetics of antigen and activity of recombinant tissue-type plasminogen activator after infusion in healthy volunteers. Arzneimittelforschung 1988; 38: 418-22
18. Koster RW, Cohen AF, Kluft C, et al. The pharmacokinetics of recombinant double chain t-PA (Duteplase): Effects of bolus injection, infusions and administration by weight in patients with myocardial infarction. Clin Pharmacol Ther 1991; 50: 267-77
19. Koster RW, Cohen AF, Hopkins G, et al. Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. Thromb Haemost 1994; 71 (5): 740-4
20. Griensven JMTv, Burggraaf J, Gerloff J, et al. Effects ofchanging liver blood flow by exercise and food on kinetics and dynamics of saruplase. Clin Pharmacol Ther 1995; 57: 381-9
21. Cohen AF, Burggraaf J, Boer AD, et al. Clearance of plasminogen activators - a major determinant of plasma concentration. Therapeutic and diagnostic implications. Ann N Y Acad Sci 1992; 667: 443-9
22. Griensven JMTv, Huisman L, Stuurman T, et al. Effects of increased liver blood flow on the kinetics and dynamics of recombinant tissue-type plasminogen activator. Clin Pharmacol Ther 1996; 60: 504-11
23. Boer AD, Kluft C, Kroon JM, et al. Liver blood flow as a major determinant of the clearance of recombinant tissue-type plasminogen activator. Thromb Haemost 1992; 67: 83-7
24. Griensven JMTv, Koster RW, Burggraaf J. et al. Effects of liver blood flow on the pharmacokinetics of tissue type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction. Clin Pharmacol Ther 1998; 63: 39-47
25. Griensven JMTV, Koster RW, Hopkins G, et al. Effect of changes in liver blood flow on the pharmacokinetics of saruplase in patients with acute myocardial infarction. Thromb Haemost 1997; 78 (3): 1015-20
26. Kuiper J, van de Bilt H, Martin U, et al. Uptake, internalisation and degradation of the novel plasminogen activator reteplase (BM 06.022). Thromb Haemost 1995; 74 (6): 1501-10
27. Martin U, Doerge L, Stegmeier K, et al. Influence of the degree of renal dysfunction on the pharmacokinetic properties of the novel recombinant plasminogen activator reteplase in rats. Drug Memb Dispos 1996; 24 (3): 288-92
28. Agnelli G, Buchanan MR, Fernandez F, et al. The thrombolytic and haemorrhagic effects of tissue type plasminogen activator: Influence of dosage regimens in rabbits. Thromb Res 1985; 40: 769-77
29. Koster RW, Stralen van R, McNeill AJ, et al. A randomised dose-ranging study of rt-PA in acute myocardial infarction. Effects on coronary patency and fibrinolytic parameters. Eur Heart J 1990; 11: 730-9
30. Collen D, Stassen JM, Larsen G. Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits. Blood 1988; 71 (1): 216-9
31. Noble S, McTavish D. Reteplase. A review of its pharmacological properties and clinical efficacy in the management of acute myocardial infarction. Drugs 1996; 52 (4): 589-605
32. Collins R, Peto R, Baigent C, et al. Aspirin, heparin and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med 1997; 336 (12): 847-60
33. Chesebro JH, Knatterud GL, Roberts R, et al. Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 1987; 76: 142-54
34. Gold HK, Leinbach RC, Garabedian HD, et al. Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. Circulation 1986; 73: 347-52
35. Braunwald E, Knatterud GL, Passamani ER, et al. Announcement of protocol change in thrombolysis in myocardial infarction trial [letter]. J Am Coll Cardiol 1987; 9 (2): 467
36. Koster RW, Cohen AF, Hopkins GR, et al. Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain. Thromb Haemost 1994; 72 (5): 740-4
37. Collen D, Topoi EJ, Tiefenbrunn AJ, et al. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomised, placebo-controlled trial. Circulation 1984; 70: 1012-7
38. Williams DO, Borer J, Braunwald E, et al. Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial. Circulation 1986; 73: 338-46
39. Ware JH, Antman EM. Equivalence trials. N Engl J Med 1997; 337 (16): 1159-61
40. Hampton JR, Schröder R, Wilcox RG. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet 1995; 346 (8971): 329-36
41. Musselman DR, Tate DA, Oberhardt BJ, et al. Differences in clot lysis among patients demonstrated in vitro with three thrombolytic agents (tissue type plasminogen activator, streptokinase and urokinase). Am J Cardiol 1994; 73: 544-9
42. Schoemaker HC, Cohen AF. Estimating impossible curves using NONMEM. Br J Clin Pharmacol 1996; 42: 283-90
43. Cannon CP, McCabe CH, Gibson CM, et al. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation 1997; 95 (2): 351-6